This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OncoGenex Slammed on Teva Partnership: BioBuzz

BOTHELL, Wash. ( TheStreet) -- Shares of OncoGenex Pharmaceuticals (OGXI - Get Report) are getting a pre-Christmas spanking Monday after the company essentially gave away its experimental prostate cancer drug to Teva Pharmaceuticals (TEVA - Get Report).

In exchange for rights to OGX-011, Teva is paying OncoGenex $30 million upfront, of which $10 million is from an equity investment. But OncoGenex has to pay Isis Pharmaceuticals (ISIS - Get Report) $10 million, which leaves OncoGenex with only $20 million.

Teva is paying for the cost of the phase III studies and will pay OncoGenex royalties on OGX-011 sales ranging from 15% to 25%. But again, OncoGenex owes Isis a mid-single digit royalty on sales, so the former's net royalty is only going to be in the teens.

Teva is a giant in the generic drug business but has no standing whatsoever in the branded cancer drug market. What seems clear is the OncoGenex shopped around OGX-011 but couldn't find any interest amongst potential A-list partners. When the drug was put on sale at a deep discount, Teva snatched it up.

OGX-011 garnered a good deal of buzz last spring after OncoGenex presented promising phase II study results in prostate cancer. The stock traded as high as $40 in August on expectations of a big partnership or an outright acquisition of the company.

The disappointing terms of the Teva deal announced Monday were clearly not what investors were hoping for. OncoGenex shares are down 25% to $22.04 in recent trading.

Incyte Licenses Drug to Eli Lilly

(At 8:18 AM EST)

Incyte (INCY) announced Monday that it has licensed a mid-stage rheumatoid arthritis drug to Eli Lilly (LLY).

Under terms of the agreement, Lilly is paying $90 million upfront to Incyte for development and marketing rights to INCB28050, which is currently in a phase II study for rheumatoid arthritis.

Incyte will also be eligible for an additional $665 million in potential milestone payments from Lilly and double-digit royalties on the drug's global sales, if approved.

The partnership between the two companies encompasses INCB28050 and certain follow-on compounds which may be developed for other autoimmune and anti-inflammatory diseases.

As a result of this transaction, Lilly expects to incur a charge to earnings in the fourth quarter of approximately 5 cents per share. The company reconfirmed its full-year 2009 earnings guidance of $3.90 to $4.00 per share on a reported basis, or $4.30 to $4.40 per share on a pro forma basis.

INCB28050 is an oral drug that inhibits JAK1 and JAK2 -- two enzymes thought to play a role in the course of rheumatoid arthritis and other inflammatory/autoimmune diseases.

Incyte's lead JAK inhibitor, INCB18424, is in Phase III development for myelofibrosis.

Pfizer Licenses Athersys Stem-Cell Drug

(At 6:46 AM EST)

Pfizer (PFE) said Monday it has licensed a stem cell therapy for inflammatory bowel disease from Athersys (ATHX).

Athersys will received $6 million upfront from Pfizer and is eligible for another $105 million in future milestone payments. Pfizer is paying the costs to develop the stem cell therapy, known as MultiStem, for inflammatory bowel disease.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
ISIS $53.68 0.00%
OGXI $3.60 0.00%
TEVA $72.00 0.00%
AAPL $122.77 0.00%
FB $94.20 -2.80%


Chart of I:DJI
DOW 17,568.53 -127.94 -0.73%
S&P 500 2,079.65 -12.01 -0.58%
NASDAQ 5,088.63 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs